<DOC>
	<DOCNO>NCT01370434</DOCNO>
	<brief_summary>Based proven efficacy ability induce rapid response various combination bortezomib include PAD combination refractory newly diagnose patient Multiple Myeloma , investigator intend investigate efficacy 2 cycle PAD combination ( Ps-341/Bortezomib , Adriamycin , Dexamethasone ) examine feasibility harvest G-CSF mobilize PBSC perform early AHCT 2 cycle PAD .</brief_summary>
	<brief_title>Two Cycles PAD Combination AHCT MM</brief_title>
	<detailed_description>1.PAD combination chemotherapy - Bortezomib 1.3 mg/m2 give intravenous bolus injection day 1 , 4 , 8 , 11 cycle . Oral intravenous dexamethasone 40 mg administer day 1-4 8-11 doxorubicin 9 mg/m2 intravenous bolus day 1-4 cycle . The cycle repeat every 3 week . A total 2 cycle plan AHCT . - For mobilization , G-CSF 10ug/kg/d alone give subcutaneous injection day 12 second PAD cycle completion harvest . Melphalan 100 mg/m2/day administer day -3 day -2 high-dose chemotherapy . -Maintenance : Thalidomide 100 - 200 mg/d 2 year</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients newly diagnose symptomatic MM ( see Appendix I ) Patients eligible AHCT . Patients measurable serum urine paraprotein . The performance status patient 70 Karnofsky performance scale Adequate hepatic renal function : serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) , serum alanine aminotransferase ( ALT ) /aspartate aminotransaminase ( AST ) value &lt; 2.5 x ULN , serum creatinine &lt; 1.5 x ULN Adequate cardiac function : ejection fraction &gt; 40 % echocardiogram radionuclide heart scan prior chemotherapy myeloma except 4 day dexamethasone 40 mg per day localize radiotherapy plasmapheresis treatment clinically significant hyperviscosity syndrome peripheral neuropathy grade 2 within 14 day enrollment . significant infection</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>MM</keyword>
</DOC>